Evidence map›Paper›PMID 36350533›Full record

ArticleAdvances in therapy2023

Characteristics, Treatment Patterns, and Clinical Outcomes of Chronic Hepatitis B Across 3 Continents: Retrospective Database Study.

Iain A Gillespie, K Arnold Chan, Yunhao Liu, Shu-Feng Hsieh, Christian Schindler, Wendy Cheng, Rose Chang, Elisabeth Kap, Eleonora Morais, Mei Sheng Duh and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Iain A GillespieEpidemiology, Value Evidence and Outcomes, GSK, Gunnels Wood Road, Stevenage, UK. iain.a.gillespie@gsk.com.ORCID http://orcid.org/0000-0002-2265-9506
K Arnold ChanHealth Data Research Center, National Taiwan University, Taipei, Taiwan.
Yunhao LiuVEO Data, Methods, and Analytics, GSK, Collegeville, PA, USA.
Shu-Feng HsiehHealth Data Research Center, National Taiwan University, Taipei, Taiwan.
Christian SchindlerWIG2 Scientific Institute for Health Economics and Health System Research, Leipzig, Germany.
Wendy ChengAnalysis Group, Inc., Boston, MA, USA.
Rose ChangAnalysis Group, Inc., Boston, MA, USA.
Elisabeth KapIQVIA Commercial GmbH & Co., Frankfurt, Germany.
Eleonora MoraisEpidemiology, Value Evidence and Outcomes, GSK, Gunnels Wood Road, Stevenage, UK.
Mei Sheng DuhAnalysis Group, Inc., Boston, MA, USA.
Suna ParkAnalysis Group, Inc., Boston, MA, USA.
Miriam KetzDtoD-Data to Decision-AG, Hamburg, Germany.
Sarah JennerReal World Solutions, IQVIA, London, UK.
Naomi BoxallReal World Solutions, IQVIA, London, UK.
Stuart KendrickGSK, Gunnels Wood Road, Stevenage, UK.
Dickens TheodoreGSK, Research Triangle Park, NC, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe prevalence of chronic hepatitis B virus (HBV) infection is high in many countries; however, robust, real-world epidemiological data are lacking. This study describes the prevalence, characteristics, treatment patterns, and long-term clinical outcomes of patients with chronic HBV infection in the US, Germany, and Taiwan.

methodsThis was a retrospective cohort analysis of three healthcare/insurance claims databases. Individuals were identified as patients with chronic HBV infection if their records contained HBV diagnostic codes from 1 January 2010 to 31 December 2012 (Germany and Taiwan) or 1 January 2013 (USA). Included patients were indexed on 1 January 2013. Patients' demographics, clinical characteristics, and healthcare utilisation were described. Treatment patterns and long-term clinical outcomes over follow-up (to 31 December 2016 or loss to follow-up) were estimated.

resultsThe prevalence of chronic HBV infection was 0.10%, 0.17%, and 2.39% in the US, Germany, and Taiwan respectively. Prevalence was very low in children, increased rapidly in adulthood, and peaked in 50- < 65 year olds before declining in the elderly. More US (16.6%) and German (15.4%) patients were HIV ± HCV coinfected than in Taiwan (4.1%). Baseline clinical characteristics and healthcare utilisation were broadly similar between countries. In total, 19.2%, 11.1%, and 5.9% of non-coinfected adult patients received treatment at index in the US, Germany, and Taiwan, respectively; most frequently with nucleos(t)ide analogue monotherapy (94.4%, 97.2%, 99.8% of treated patients, respectively) and rarely with interferons (0.27%, 1.63%, and 0.06%, respectively). Untreated Taiwanese patients were more likely to remain untreated than elsewhere, and treated Taiwanese patients were less likely to persist with therapy. Generally, the cumulative incidence of long-term clinical outcomes was lowest in Germany.

conclusionThis study provides a contemporary, real-world, intercontinental snapshot of chronic HBV infection. Long-term sequelae occurred in all populations, and treatment levels were low, suggesting an unmet need for (or access to) effective treatments.

Indexed as

Hepatitis B, ChronicAdultAgedAntiviral AgentsChildCohort StudiesHepatitis B virusHumansRetrospective StudiesTreatment OutcomeAntiviral AgentsEpidemiologyHepatitis B virusPrevalenceSequelaeTherapeutics

Identifiers

PMID36350533
PMCPMC9898346

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.